These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20210024)

  • 1. [Cytostatic-assisted myelosuppression using dicarbamin, an oral hematoprotector (experimental study)].
    Treshchalin ID; Bodiagin DA; Pereverzeva ER; Treshchalin MI; Nebol'sin VE
    Vopr Onkol; 2009; 55(6):769-74. PubMed ID: 20210024
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanisms of protective effect of Dicarbamin on the blood system in cytostatic treatment.
    Nebolsin VE; Zhdanov VV; Zyuzkov GN; Udut EV; Khrichkova TY; Simanina EV; Stavrova LA; Miroshnichenko LA; Chaikovskiy AV; Dygai AM
    Bull Exp Biol Med; 2011 Jan; 150(3):343-7. PubMed ID: 21240350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of granulocytic colony-stimulating factor on cytostatic-suppressed granulocytopoiesis under conditions of exhausted catecholamine depot.
    Dygai AM; Skurikhin EG; Pershina OV; Simanina EV; Minakova MY; Ermakova NN; Firsova TV; Khmelevskay ES
    Bull Exp Biol Med; 2009 May; 147(5):609-12. PubMed ID: 19907751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Growth dynamics of transplantable murine tumors in the course of dicarbamin-protected chemotherapy].
    Sedakova LA; Treshchalina EM; Sitdikova SM; Nebol'sin VE
    Vopr Onkol; 2010; 56(5):591-2, 594-6. PubMed ID: 21137241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects and mechanisms of hemopoiesis-stimulating activity of immobilized oligonucleotides under conditions of cytostatic myelosuppression.
    Dygai AM; Goldberg VE; Artamonov AV; Bekarev AA; Vereschagin EI; Madonov PG; Skurikhin EG; Pershina OV; Andreeva TV; Khmelevskaya ES; Ermakova NN
    Bull Exp Biol Med; 2012 Feb; 152(4):451-5. PubMed ID: 22803109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow morphology during haematopoietic stem cell mobilisation with cyclophosphamide in mice.
    Karbicka A; Marchlewicz M; Wiszniewska B; Machaliński B
    Folia Morphol (Warsz); 2003 Nov; 62(4):435-7. PubMed ID: 14655135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hematoprotective effectiveness of dicarbamin in experimental post-radiation bone marrow syndrome].
    Moiseeva IIa; Zinov'ev AI; Nikishin SA; Nebol'sin VE
    Vopr Onkol; 2012; 58(1):81-4. PubMed ID: 22629834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hemoprotection with dicarbamine: shielding of bone marrow hemopoietic cells from apoptosis and induction of cell differentiation in myelosuppressive effect of cyclophosphamide].
    Raĭkhlin NT; Bukaeva IA; Sitdikova SM; Nebol'sin VE
    Vopr Onkol; 2011; 57(4):497-500. PubMed ID: 22191241
    [No Abstract]   [Full Text] [Related]  

  • 9. [The effects of ICA on the cell-immunosuppressive and bone-marrow-suppressive mice after chemotherapy].
    Zhao LM; Ji X; Shan BE; Han LN; Pan XM; Peng H; Ma M
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Oct; 26(10):976-9. PubMed ID: 20937233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of regulation of hemopoiesis during experimental cytostatic myelosuppression induced by carboplatin.
    Dygai AM; Zhdanov VV; Zyuz'kov GN; Udut EV; Simanina EV; Gur'yantseva LA; Khrichkova TY; Stavrova LA; Epshtein OI; Sergeeva SA; Gol'dberg ED
    Bull Exp Biol Med; 2007 May; 143(5):581-4. PubMed ID: 18239772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new therapeutic program in advanced ovarian cancer. Good results with decentralized cytostatic therapy].
    Henic E; Högberg T
    Lakartidningen; 1998 May; 95(22):2574-8. PubMed ID: 9640935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and delayed effects of carboplatin on the blood system.
    Karpova GV; Fomina TI; Voronova OL; Abramova EV; Loskutova OP
    Bull Exp Biol Med; 2001 Nov; 132(5):1065-9. PubMed ID: 11865323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematologic and cytogenetic effects of androgens in cytostatic-treated mice (the micronucleus test).
    Ioan D
    Endocrinologie; 1981; 19(3):179-81. PubMed ID: 6794141
    [No Abstract]   [Full Text] [Related]  

  • 14. [Expression of the bone marrow macrophage receptors during cytostatic myelosuppression].
    Gol'dberg ED; Bel'skiĭ IuP; Danilets MG; Dygaĭ AM; Zhdanov VV; Kusmartsev SA
    Biull Eksp Biol Med; 1998 Jul; 126(7):25-7. PubMed ID: 9777188
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bone-marrow protective effect of asparagine in experimental administration of imuran].
    Fodor O; Goia A; Tănăsescu R; Părău N; Goia E
    Stud Cercet Med Interna; 1973; 14(4):329-38. PubMed ID: 4727207
    [No Abstract]   [Full Text] [Related]  

  • 16. [Stem cell kinetics of bone marrow in relation to cytostatic treatment].
    Laerum OD
    Tidsskr Nor Laegeforen; 1971 Jun; 91(16):1207-9 passim. PubMed ID: 4935674
    [No Abstract]   [Full Text] [Related]  

  • 17. [The blood-simulating properties of a recombinant colony-stimulating factor and glycyram during cytostatic myelosuppression].
    Dygaĭ AM; Zhdanov VV; Masycheva VI; Minakova MIu; Romanov VP; Pustoshilova NM; Simanina EV; Agafonov VI; Gol'dberg ED
    Eksp Klin Farmakol; 1999; 62(1):34-7. PubMed ID: 10198763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weakening of genetic resistance. II. The effect of injection of the macrophage toxic agents silica and carragheenan and the cytostatic drugs cyclophosphamide, busulphan and vinblastin.
    Buurman WA; van Bruggen I
    Exp Hematol; 1976 Nov; 4(6):382-92. PubMed ID: 186293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The immunocorrective activity of myelopeptide-1 and myelopeptide-2 in cyclophosphane-treated mice].
    Shanurin SIu; Belevskaia RG; Mikhaĭlova AA; Shanurin MIu
    Eksp Klin Farmakol; 1995; 58(5):53-6. PubMed ID: 8704592
    [No Abstract]   [Full Text] [Related]  

  • 20. Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity.
    Mumtaz IM; Hoyer BF; Panne D; Moser K; Winter O; Cheng QY; Yoshida T; Burmester GR; Radbruch A; Manz RA; Hiepe F
    J Autoimmun; 2012 Sep; 39(3):180-8. PubMed ID: 22727274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.